Institut d'Investigacions Biomèdiques August Pi i Sunyer.
REF: PhD 11

Therapeutic strategies for Huntington''s disease

Title:
Postdoctoral Research Fellow
Hours of work:
37.5 hours per week (exluding lunch hours)
Annual leave:
24 days per annum plus statutory days
Location:
Villarroel 170, 08036 Barcelona
Accountable to:
Professor Jordi Alberch Vié
Contract:
Up to 3 years, by IDIBAPS
Salary:
38.000 € plus housing facilities
PDF version
Closing date: August, 31st 2010
Apply (Read eligibility criteria)

Job summary

A postdoctoral position is available in Professor Jordi Alberch laboratory. The position involves working with a team of scientists studying therapeutic strategies for neurodegenerative disorders, particularly for motor disorders affecting the basal ganglia.

The programme is a continuation of works recently published in Canals et al., 2004, J.Neurosci., 24:7727-39; del Toro et al., 2006, J. Neurosci., 26:12748-57; del Toro et al., 2009, Mol Biol Cell., 20:1478-92; Giralt et al., 2010, Gene Ther., Epub ahead of print; Gines et al., 2010, J Biol Chem., Epub ahead of print, which have underscore that BDNF is involved in Huntington’s disease (HD) and it is a good candidate to be used as a neuroprotective tool for the treatment of HD.

The present project will be performed in the laboratory of Pathophysiology of Neurodegenerative disorders in the Department of Cell Biology, Immunology and Neurosciences at the , Medical School, University of Barcelona. This multidisciplinary group is leaded by Dr Jordi Alberch, Professor, with more than 20 years of experience in the study of the regulation of trophic factors expression and their neuroprotective effects in different experimental models of neurodegenerative diseases of the basal ganglia. In the last years, we have focused our studies on the relevance of BDNF in the pathophysiology of HD. To show a direct involvement of BDNF in the pathophysiology of HD, we developed a new transgenic mouse model of HD with lower levels of BDNF. We crossed the R6/1 mouse model of HD with BDNF+/- mice, showing that reduced BDNF levels induced an early onset and more severe pathology. We have also demonstrated that the pathological features of HD can be reverted by exogenous BDNF delivery by direct intracerebral injections and by ex vivo cell-mediated strategies. We have also recently developed a new approach by obtaining engineered astrocytes that express high levels of BDNF under the GFAP promoter.

The group is integrated in the Spanish network of neurodegenerative disorders (CIBERNED) and in the Spanish Cell Therapy network (RETICS; TERCEL). These two networks provide a collaborative environment to successfully achieve our objectives.

The purpose of this programme of work will be:

2. The project is likely to involve some or all of the following techniques:

Main Duties

To conduct research investigating the potential application of different strategies of BDNF and related molecules as therapy approaches for neurodegenerative disorders.

Duties and Responsabilities

Person specification

Knowledge and Qualifications

Essential:

Desirable:

Skills

Essential:

Desirable:

Experience

Essential:

Experience of working in a research environment

Desirable:

Experience of multi-disciplinary working

Personal Qualities

Essential:

Apply (Read eligibility criteria)
Idibaps
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)
Villarroel, 170 · 08036 Barcelona
+34 93 227 57 07